Please have answers prepared to the following questions:
1.  What is the premise of this case?
2.  With the information available to Chen in 2009, do you think her decision to invest $45 million to diversify RoboTech into medical robotics was appropriate?
3.  How would you evaluate the company’s first three years in the U.S. medical device market?  What do you think it has done most effectively?  Where has it fallen short?
4.  What should Chen do now?  How should the company move forward into 2017 and beyond? Which, if any, of the proposed capital investments should it make?
5.  What strategic lessons can be derived from this case?